Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H.

Haematologica. 2019 May;104(5):947-954. doi: 10.3324/haematol.2018.204602. Epub 2018 Nov 15.

2.

Patchy hematopoiesis mimicking bone metastasis.

Cornelisse AC, Te Boekhorst PAW.

Blood. 2018 Oct 11;132(15):1626. doi: 10.1182/blood-2018-06-856823. No abstract available.

PMID:
30309877
3.

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, Brümmendorf TH.

Blood Adv. 2018 Jul 10;2(13):1572-1579. doi: 10.1182/bloodadvances.2018017772.

4.

Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial.

van der Meer PF, Ypma PF, van Geloven N, van Hilten JA, van Wordragen-Vlaswinkel RJ, Eissen O, Zwaginga JJ, Trus M, Beckers EAM, Te Boekhorst P, Tinmouth A, Lin Y, Hsia C, Lee D, Norris PJ, Goodrich RP, Brand A, Hervig T, Heddle NM, van der Bom JG, Kerkhoffs JH.

Blood. 2018 Jul 12;132(2):223-231. doi: 10.1182/blood-2018-02-831289. Epub 2018 May 17.

5.

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN.

Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20.

PMID:
28336242
6.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

7.

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA.

J Clin Oncol. 2016 Jan 10;34(2):151-9. doi: 10.1200/JCO.2015.62.9337. Epub 2015 Nov 23.

8.

Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study).

Schonewille H, Honohan Á, van der Watering LM, Hudig F, Te Boekhorst PA, Koopman-van Gemert AW, Brand A.

Transfusion. 2016 Feb;56(2):311-20. doi: 10.1111/trf.13347. Epub 2015 Oct 7.

PMID:
26442648
9.

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.

Slot S, Smits K, van de Donk NW, Witte BI, Raymakers R, Janssen JJ, Broers AE, Te Boekhorst PA, Zweegman S.

Bone Marrow Transplant. 2015 Nov;50(11):1424-31. doi: 10.1038/bmt.2015.172. Epub 2015 Aug 3.

PMID:
26237165
10.

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.

Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, Koene HR; Dutch HOVON 64 study group.

Haematologica. 2015 Mar;100(3):e90-2. doi: 10.3324/haematol.2014.110213. Epub 2014 Nov 25. No abstract available.

11.

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.

Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Cañizo C, Guerci-Bresler A, Nilsson L, Lübbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, Göhring G, Fu T, Benettaib B, Hellström-Lindberg E, Fenaux P.

Eur J Haematol. 2014 Nov;93(5):429-38. doi: 10.1111/ejh.12380. Epub 2014 Jun 9.

12.

Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production.

Tjon AS, van Gent R, Jaadar H, Martin van Hagen P, Mancham S, van der Laan LJ, te Boekhorst PA, Metselaar HJ, Kwekkeboom J.

J Immunol. 2014 Jun 15;192(12):5625-34. doi: 10.4049/jimmunol.1301260. Epub 2014 May 7.

13.

The First Fifty ABO Blood Group Incompatible Kidney Transplantations: The Rotterdam Experience.

van Agteren M, Weimar W, de Weerd AE, Te Boekhorst PA, Ijzermans JN, van de Wetering J, Betjes MG.

J Transplant. 2014;2014:913902. doi: 10.1155/2014/913902. Epub 2014 Feb 6.

14.

Hepatosplenic T-cell lymphoma.

te Boekhorst PA, van Lom K.

Br J Haematol. 2013 Nov;163(4):422. doi: 10.1111/bjh.12550. Epub 2013 Aug 30. No abstract available.

PMID:
24033076
15.

[Thrombocytopenia during pregnancy].

Rokx C, Swart RM, van Houten AA, Leys MB, Duvekot JJ, Te Boekhorst PA.

Ned Tijdschr Geneeskd. 2013;157(33):A6445. Dutch.

PMID:
23945435
16.

Does standard intravenous calcium gluconate administration during peripheral blood stem cell collection reduce the chance of a citrate reaction?

Brunner-Spiering JD, Grootes ME, te Boekhorst PA, de Greef GE.

Transfus Apher Sci. 2013 Apr;48(2):199. doi: 10.1016/j.transci.2013.03.001. Epub 2013 Mar 25. No abstract available.

PMID:
23809834
17.

Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells.

Tjon AS, Tha-In T, Metselaar HJ, van Gent R, van der Laan LJ, Groothuismink ZM, te Boekhorst PA, van Hagen PM, Kwekkeboom J.

Clin Exp Immunol. 2013 Aug;173(2):259-67. doi: 10.1111/cei.12102.

18.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA.

J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L].

19.

Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.

Abouyahya I, Alhan C, Westers TM, te Boekhorst PA, Kappers-Klunne MC, Coenen JL, Heyning FH, Huls GA, de Wolf JT, Imholz AL, Koene HR, Veth G, de Kruijf EJ, Muus P, Planken EV, Segeren CM, Vasmel WL, van der Velden AM, Velders GA, Koedam J, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Lymphoma. 2013 Apr;54(4):874-7. doi: 10.3109/10428194.2012.728702. Epub 2012 Sep 28. No abstract available.

PMID:
22971215
20.

High-dose intravenous immunoglobulin does not reduce the numbers of circulating CD14(+)CD16(++) monocytes in patients with inflammatory disorders.

Tjon AS, Metselaar HJ, te Boekhorst PA, van Hagen PM, Kwekkeboom J.

Clin Immunol. 2012 Oct;145(1):11-2. doi: 10.1016/j.clim.2012.07.008. Epub 2012 Jul 24. No abstract available. Erratum in: Clin Immunol. 2013 Apr;147(1):69.

PMID:
22885147
21.

Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: Is eculizumab indicated?

Bellido M, van der Velden VH, Leebeek FW, te Boekhorst PA.

Ann Hematol. 2012 Dec;91(12):1969-70. doi: 10.1007/s00277-012-1511-5. Epub 2012 Jul 4. No abstract available.

22.

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms.

Bellido M, Te Boekhorst PA.

Adv Hematol. 2012;2012:535709. doi: 10.1155/2012/535709. Epub 2012 Feb 16.

23.

Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab.

van Bijnen ST, van Rijn RS, Koljenovic S, te Boekhorst P, de Witte T, Muus P.

Br J Haematol. 2012 Jun;157(6):762-3. doi: 10.1111/j.1365-2141.2012.09073.x. Epub 2012 Feb 29. No abstract available.

PMID:
22372429
24.

Thrombopoietin-receptor agonists for immune thrombocytopenia.

Jansen AJ, Swart RM, te Boekhorst PA.

N Engl J Med. 2011 Dec 8;365(23):2240-1. doi: 10.1056/NEJMc1112230. No abstract available.

PMID:
22150056
25.

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.

Michel M, te Boekhorst PA, Janssens A, Pabinger-Fasching I, Sanz MA, Nie K, Kreuzbauer G.

Hematology. 2011 Sep;16(5):274-7. doi: 10.1179/102453311X13025568942005.

26.

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group.

Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13.

27.

Evidence for acute neurotoxicity after chemotherapy.

Petzold A, Mondria T, Kuhle J, Rocca MA, Cornelissen J, te Boekhorst P, Lowenberg B, Giovannoni G, Filippi M, Kappos L, Hintzen R.

Ann Neurol. 2010 Dec;68(6):806-15. doi: 10.1002/ana.22169.

PMID:
21194151
28.

Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.

Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ; Dutch - Belgian HOVON cooperative group.

Br J Haematol. 2010 Jul;150(2):209-17. doi: 10.1111/j.1365-2141.2010.08227.x. Epub 2010 May 9.

PMID:
20507310
29.

Coma in thrombotic thrombocytopenic purpura.

de Jong FJ, Te Boekhorst PA, Dippel DW, Jacobs BC.

BMJ Case Rep. 2010 Nov 23;2010. pii: bcr0620103113. doi: 10.1136/bcr.06.2010.3113.

30.

Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis.

Mondria T, Lamers CH, te Boekhorst PA, Gratama JW, Hintzen RQ.

J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1013-5. doi: 10.1136/jnnp.2007.133520. Epub 2008 Jan 25.

PMID:
18223013
31.

A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis.

Rocca MA, Mondria T, Valsasina P, Sormani MP, Flach ZH, Te Boekhorst PA, Comi G, Hintzen RQ, Filippi M.

AJNR Am J Neuroradiol. 2007 Oct;28(9):1659-61. Epub 2007 Sep 20.

32.

Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines.

Brinkman DM, Jol-van der Zijde CM, ten Dam MM, te Boekhorst PA, ten Cate R, Wulffraat NM, Hintzen RQ, Vossen JM, van Tol MJ.

J Clin Immunol. 2007 Nov;27(6):647-58. Epub 2007 Aug 10.

33.

Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.

Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E, Carreras E, Saiz A, Löwenberg B, te Boekhorst PA, Gualandio F, Openshaw H, Longo G, Pagliai F, Massacesi L, Deconink E, Ouyang J, Nagore FJ, Besalduch J, Lisukov IA, Bonini A, Merelli E, Slavino S, Gratwohl A, Passweg J, Tyndall A, Steck AJ, Andolina M, Capobianco M, Martin JL, Lugaresi A, Meucci G, Sáez RA, Clark RE, Fernandez MN, Fouillard L, Herstenstein B, Koza V, Cocco E, Baurmann H, Mancardi GL; Autoimmune Diseases Working Party of EBMT.

Mult Scler. 2006 Dec;12(6):814-23.

PMID:
17263012
34.

T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem cell transplants.

Te Boekhorst PA, Lamers CH, Schipperus MR, Hintzen RQ, van der Holt B, Cornelissen JJ, Löwenberg B, Gratama JW.

Bone Marrow Transplant. 2006 Apr;37(8):763-72.

PMID:
16518423
35.

Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.

Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Meché FG, Cornelissen J, Hop WC, Löwenberg B, Hintzen RQ.

J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):46-50.

36.

Clinical significance of bacteriologic screening in platelet concentrates.

te Boekhorst PA, Beckers EA, Vos MC, Vermeij H, van Rhenen DJ.

Transfusion. 2005 Apr;45(4):514-9.

PMID:
15819671
37.

[Reports of transfusion incidents: experiences from the first year of hemovigilance in the region of the former ZWN (South West Netherlands) blood bank in Rotterdam].

Beckers EA, Dinkelaar RB, te Boekhorst PA, van Ingen HE, van Rhenen DJ.

Ned Tijdschr Geneeskd. 2003 Aug 2;147(31):1508-12. Dutch.

PMID:
12924082
38.

Hepatotoxicity of parenteral gold therapy in rheumatoid arthritis: a case report and review of the literature.

te Boekhorst PA, Barrera P, Laan RF, van de Putte LB.

Clin Exp Rheumatol. 1999 May-Jun;17(3):359-62. Review.

PMID:
10410273
39.

MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia.

van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PA, Pieters R, Schoester M, Löwenberg B, Sonneveld P.

Br J Haematol. 1997 Oct;99(1):76-83.

PMID:
9359506
40.

Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.

te Boekhorst PA, Löwenberg B, van Kapel J, Nooter K, Sonneveld P.

Leukemia. 1995 Jun;9(6):1025-31.

PMID:
7541095
42.

[Multidrug resistance in hematological malignancies: prognostic significance and the effect of resistance-modulating drugs].

Sonneveld P, te Boekhorst PA.

Ned Tijdschr Geneeskd. 1994 Mar 5;138(10):508-12. Review. Dutch. No abstract available.

PMID:
7908127
43.

Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.

te Boekhorst PA, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Löwenberg B, Sonneveld P.

Blood. 1993 Nov 15;82(10):3157-62.

44.
45.

Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.

te Boekhorst PA, Löwenberg B, Vlastuin M, Sonneveld P.

Leukemia. 1993 Aug;7(8):1191-8.

PMID:
7688839
46.

Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression.

Adriaansen HJ, te Boekhorst PA, Hagemeijer AM, van der Schoot CE, Delwel HR, van Dongen JJ.

Blood. 1993 Jun 1;81(11):3043-51.

47.

Supplemental Content

Loading ...
Support Center